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Blunted Erythropoietin Production and Decreased Erythropoiesis 
in Early Pregnancy 
By Yves Beguin, Gyorgyi Lipscei, Henri Thoumsin, and Georges Fillet 
After decreasing in the first trimester of pregnancy, the total 
red blood cell mass increases in the second and third 
trimesters to peak at term at about 120% to 125% of 
nonpregnant values, but how this is brought about by 
changes in the rate of erythropoiesis is not known. We 
evaluated erythropoiesis by measuring serum transferrin 
receptor (TfR) levels in 406 women during normal pregnancy 
(N = 317). at delivery (N = 63). or in the early postpartum 
(N = 27). Despite the presence of the placenta and the 
frequent occurrence of iron deficiency, TfR levels remained 
low in the first two trimesters and increased in the third 
trimester and at delivery. To explain why erythropoiesic 
activity was relatively low in early pregnancy, we also 
REGNANCY CAUSES an increase in plasma volume P and red blood cell (RBC) mass, which reach, respec- 
tively, 150% and 120% to 125% of nonpregnant values near 
However, the total RBC mass first decreases in 
early pregnancy, before gradually returning to nonpregnant 
values by week 30 and further increasing in late pregnancy: 
Because the RBC lifespan remains unchanged during 
pregnancy: modifications in the RBC mass must be pre- 
ceded by changes in the rate of erythropoiesis. Because 
until recently only ferrokinetics could provide a quantita- 
tive assessment of erythropoiesis, no measurement of eryth- 
ropoiesis has been performed during pregnancy, except by 
reticulocyte counts: which are only of semiquantitative 
value. The measurement of serum transferrin receptor 
(TW) levels has recently been proposed as a convenient 
method to monitor erythropoiesis in animal and in hu- 
mans.”’ In the present study, we measured TfR levels in 
pregnant women and found them to be significantly de- 
creased in the first part of pregnancy as compared with 
controls. Production of erythroid cells depends on stimula- 
tion by erythropoietin (Epo) produced by the kidney in 
response to hypoxia.’O Previous studies in small groups of 
women, including one by us,” have shown increased Epo 
levels in pregnant as compared with nonpregnant 
w0men16,~*-~’ but the relationship of Epo to the hematocrit 
(Hct) often was not assessed. We therefore evaluated 
serum Epo levels in relation to the degree of anemia and 
found relatively low levels as compared with control women. 
This finding suggests that blunted Epo production could be 
respocsible for the low erythropoietic activity observed in 
early pregnancy. 
SUBJECTS AND METHODS 
Subjects. We studied 406 women who gave their consent to 
having blood drawn for hematologic tests while undergoing routine 
antenatal and obstetrical care. Mean age was 27 years (range 15 to 
45 years). Gestational age, as established by one or more ultra- 
sound scans, ranged from 5 to 42 weeks. Erythropoiesis was 
evaluated during pregnancy (N = 317), during labor leading to 
vaginal delivery (N = 63), as well as on day 7 postpartum (N = 27). 
Control Epo samples were obtained from 74 women with Hct 
within the 25% to 44% range. This control group included 33 
normal adult subjects who had not donated blood in the last 3 
months, and 41 women with hypoplasticlaplastic (N = 9), he- 
measured serum immunoreactive erythropoietin (Epo) in 
relation to the degree of anemia. There was a very strong 
correlation bgtween serum TfR and Epo levels in the entire 
group (r = .59, P < .0001) as well as in each period of 
pregnancy. Epp levels remained low for the degree of anemia 
and did not correlate with hematocrit in the first two 
trimesters, but recovered afterwards. In the early postpar- 
tum, Epo prodpction and erythropoiesis were normal. We 
conclude that: (1) erythropoiesis is decreased in the first part 
of pregnancy but increases afterwards; and (2) blunted Epo 
production in early pregnancy could be responsible for that 
observation. 
o 1991 by The American Society of Hematology. 
molytic (N = 7), dyserythropoietic (N = 9), or iron-deficient ane- 
mia (N = 16), who had not received RBC transfusions in the 
preceding week. Control TW samples were also obtained from 43 
healthy women with normal Hct and serum ferritin (12 to 120 
ng/mL). 
Human placental receptor-transferrin complex was 
purified as described elsewhere16 and injected repeatedly into 
rabbits. Serum IgG were isolated from rabbit serum” and transfer- 
rin antibodies were removed by passing through a column of 
human diferric transferrin coupled to -gel 15 (Bio-Rad, Rich- 
mond, CA). Characterization of the plasma T W  and receptor 
antibody has been described elsewhere.*-’ 
An enzyme-linked immunosorbent assay (ELISA)9 was used 
with minor modifications to measure serum levels of TW. Immuno- 
plates I with certificate (Nunc Intermed, Roskilde, Denmark) were 
used. The aliquots of blanks, standards, and unknown samples 
were added using a Digiflex automatic pipetor (Micromedic 
System, Philadelphia, PA). Standards were diluted to between 5 
and 100 ng/mL and unknown sera were diluted 150 to 1:2,000 with 
0.15 m o m  phosphate-buffered saline (PBS) (pH 7.4) containing 
0.5% bovine serum albumin and 0.05% Tween 20. After color 
development, differential absorbance was read in dual wave length 
mode at 492 and 690 in a Titertek Multiskan MCCi340 plate reader 
(Flow Laboratories, Herts, England). Each sample was run in 
triplicate. The between-assay variability (coefficient of variation) 
was 7.2% when the same control sample was measured in each 
plate. Because the standard consisted of a complex of receptor and 
transferrin molecules, all TfR values given are actually receptor- 
complex values. 
Epo assay. Circulating Epo levels were measured by a commer- 
cially available radioimmunoassay (Incstar Corp, Stillwater, MN) 
TfR assay. 
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that uses recombinant human Epo (rHuEpo) for tracer and 
standards. Samples are incubated with rabbit anti-Epo serum for 2 
hours at room temperature before Epo tracer is added. After 
overnight incubation, goat antirabbit serum is added. After centrif- 
ugation, the unbound tracer is removed by decantation and the 
pellet is counted. Several samples had to be diluted 1:lO. Twelve 
control samples were run in each assay, with a between-assay 
coefficient of variation ranging from 10.3% to 14.1%. 
Serum iron and total iron-binding capacity 
(TIBC) were measured by standard Serum ferritin 
was measured by a radioimmunoassay.z0 
Log transformed Epo and TfR values were 
used in statistical analyses. Student’s t-tests, with pooled or 
separated variances as appropriate, were used to compare two 
groups. Analysis of variance (ANOVA), with Snedecor’s F-test or 
Welch’s test as appropriate, was used to compare more than two 
groups. Two-way analysis of variance was used to assess the effect 
of iron stores on TW values within each period studied. Pearson 
and likelihood-ratio xz tests were used to measure associations in 
two-way or multiway frequency tables. The r correlation coefficient 
between two variables was computed in least squares regression 
equations. The slopes and y-intercepts of the regression lines 
between log(Epo) and Hct in controls and study subjects were 
tested for equality among groups by Student’s t-tests in an analysis 
of covariance, using the BMDP 1V program of the BMDP 
Statistical Software (University of California). A multivariate 





Mean serum TfR level in 43 normal women 
was 6,940 5 1,480 ng/mL (range, 4,300 to 11,450). Thirty- 
three normal control women had a mean Hct of 39.5% & 
2.1% (M & SD) and a mean Epo level of 16.4 ? 4.1 
mU/mL, while Epo levels in 41 nonpregnant anemic women 
ranged from 10 to 237 mU/mL. The following regression 
(N = 74, r = -.88, P < .0001) was obtained between Epo 
(mU/mL) and Hct (%): log(Epo) = 3.8279 - (0.0662 Hct). 
Based on this formula, a predicted log(Epo) value was 
derived for each sample and the O/F’ ratio of observed/ 
predicted log(Epo) ranged from 0.80 to 1.20. Consequently, 
O/P ratios in study subjects were considered abnormal if 
lower than 0.80. 
Study subjects. Table 1 displays Hct, iron status, serum 
TfR and Epo levels, as well as O/P ratios in groups of 
pregnant women. As compared with controls, Hct de- 
creased in the first and further so in the second and third 
trimesters, before reincreasing at delivery and on day 7 
postpartum (P < .0001 for comparison between periods of 
Controls. 
pregnancy). Transferrin saturation as well as serum ferritin 
levels decreased throughout pregnancy. In the first trimes- 
ter, only 8% of women were iron deficient (serum ferri- 
tin < 12 )L&). This figure rapidly increased to 27% in the 
second and 59% in the third trimester (P < .0001). 
TfR levels were decreased in early pregnancy, normal- 
ized in the first part of the third trimester, and increased 
slightly beyond normal values in late pregnancy, at delivery, 
and in the early postpartum (P < .001). The evolution of 
Hct, TfR, Epo, and O/P ratio throughout pregnancy is 
illustrated in Fig 1. The fraction of cases with reduced 
erythropoiesis (TfR < 4,300 p&L) was 34%, 48%, 16%, 
lo%, and only 1%, respectively, during weeks 5 through 12, 
13 through 20,21 through 28,29 through 32,33 through 36, 
and after week 37 (P < .OOOl). The effect of iron status on 
serum TfR levels was analyzed in two-way analysis of 
variance (Table 2). Within each trimester of pregnancy, 
women with deficient iron status (serum ferritin < 12 
&L) had higher TfR levels than women with marginal 
status (ferritin 12 to 19 p,g/mL) and even more so than those 
with normal iron stores (ferritin 2 20 pg/mL). Both time of 
pregnancy and iron status were significant determinants of 
TfR levels (P < .0001) and there was no interaction be- 
tween the two. 
Epo levels were higher during pregnancy (31.4 2 20.5 
mU/mL), at delivery (33.9 ? 22.3 mU/mL), and on day 7 
postpartum (35.1 & 34.7 mU/mL) than in normal women 
(P < .001). Epo levels increased steadily (Fig 1) through- 
out pregnancy and into third trimester values (P < .001), 
but remained relatively stable among third trimester, deliv- 
ery, and early postpartum values (not significant [NS]). The 
mean O/P ratio was significantly reduced in the first two 
trimesters (P  < .001) but returned to normal values in the 
third trimester, at delivery, and on day 7 postpartum. Epo 
levels were relatively low for the degree of anemia (O/P 
ratio < 0.80) in 10% of the cases in the third trimester, and 
25% of the cases in the first two trimesters (P < 0.01). In 
the 9 to 16 week period (Fig l), the percentage of cases with 
abnormal O/P ratios peaked to 34%. 
Figure 2 displays regression lines between Epo levels and 
Hct in groups of pregnant women as compared with control 
women. The inverse linear relationship between log(Epo) 
and Hct was not significant in the first (r = -.01) and 
second ( r =  -.16) trimesters, was present but with a 
reduced slope (P < .001 for difference in slopes) during the 
third trimester (r = -.41, P < .0001), and was normal 
Table 1. Hct, Iron Status, Erythropoiesis, and Serum Epo Values in Controls and Pregnant Women 
Pregnant Women 
Controls 1st Trimester 2nd Trimester 3rd Trimester Delivery Postpartum PValue 
N 43 53 108 156 110 26 
Hct (Yo) 39.5 ? 2.1 36.3 f 3.4 34.4 f 2.4 34.2 ? 3.0 36.8 f 3.2 36.1 ? 4.0 < ,0001 
Tf saturation (%) 29e 12 23 f 11 19 f 10 17 f 8 14 f 8 < .0001 
Ferritin (p,g/L) 33 2 20 44 ? 30 26 f 24 14 f 14 20 t 16 16 i 13 < ,0001 
Epo (mU/mL) 16.4 2 4.1 19.1 ? 6.2 28.4 ? 15.5 37.7 f 24.2 33.9 f 22.3 35.1 ? 34.7 <.0001 
TfR (rg/L) 6,940 2 1,480 5,350 f 2,360 5,130 ? 1,480 7,170 f 2,990 9,200 ? 3,420 8,380 f 3,220 <.0001 
O/P ratio 1.00 -c 0.10 0.91 2 0.17 0.92 2 0.14 0.98 f 0.14 1.04 ? 0.21 l.OO? 0.16 <.0001 
Pvalues are given for comparison between groups of pregnant women. 
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n0 1. Evohrhn d Hct m towh, Epo kwk. and Epo O/Protios 
I*- : SEMI *- m a m y .  n compand w)th m a l  
contrd vrlue8. 
(slopes and y-intcrccpts not significantly dificrcnt from 
controls) in thc carly postpartum ( r  = -.74. P < .OOOl). 
Thc rclationship was also nortniil in thc 28 womcn sampled 
h c y n d  wcck 37 ( r  = -.70, P < .(loOl). 
Thcrc was a vcry strong corrcliition hctwccn strum Epo 
and TfR lcvcls in thc cntirc group of prcgniint womcn 
( r  = .SY.P < .(WWII).asw~lliisinthclirst(r = A8.P < .O()l). 
scccmd ( r  = 56. P < .(Mol), and third ( r  = 54 .  I' < .CnWll) 
trimcstcrs. iit timc of dclivcry ( r  = 56. P < .MM)l). or  on 
day 7 postpartum ( r  = .48. P < .(MI). Thcrc was a striking 
piirallclism hctwccn Epo OP ratio and TfR lcvcls through- 
out prcgniincy (Fig I ) .  TfR also mrrclatcd ncgativcly with 
paramctcrs of iron status such as .ScFc. transfcrrin s;iturii- 
tion. and serum fcrritin ( P  < .(MI). hut this was mmtly 
ohscwctl in thc third trimcstcr. Thc rcliitionship hctwccn 
lict and TfR lcvcls was not significiint in thc first ( r  = - .W) 
10M.2 HhetdlronStmnonsOm"L.cnkA+cording 
ton- d ~ . g c u n ~ y  
Tlme 01 Reg- 
111 2nd 3ld P 
T i r m i a  T"m Tr1nvrrr v.lu 
Iron flatus 
Mcient  7.590 r. 6.810. 5.880 2 1.400 8.286 : 3.286 
Marginal 5,490 : 2.000 5.870 : 1,640 < . m 1  
Normal 5.040 : 1.690 6.570 2 1.060 5.660 2 1.710 
P value < .0001 
'Deficient and marginal iron flatus combined (N - 7). 
m2. R . ) . t k m M p ~ E p o t o w h . d H c t h l t t u f k r t h k m -  
1.r (I), wcond tltmostw (111. chlrd th..tw (llll. m d  on d.v 7 
portpwhrm (PP). Control r u m  010 repnuntd by (h.h 95% 
confid.mo h i t s  (shmded am.). 
and scmnd ( r  = -. 14) trimcstcrs. and was wcak in the third 
trimcstcr ( r  = -26. P < Ill). In multivariiitc stcpwisc 
rcgrcssion iinalysis ( r  = Hi). scrum Epo contrihutcd thc 
most to thc prediction of scrum TfR (chanpc in i: 3s) .  
transfcrrin siituribtion (chiinpc in i: .OX). and fcrritin 
(chiingc in i: .02) wmchow cnhanccd precision. whilc Hct 
and wcck of prcpnancy did not add sipnificiincc. 
DISCUSSION 
Prcgnancy causcs mnsidcrahlc iiltcrations in plasma 
volumc iind RRC mass. Thcrc is littlc chiinpc in plasma 
volumc hcforc wcck 16. hut thcn a stcadv incrcasc titkcs 
PliiCc to 120C; of nonprcgnant valucs by wcck 20. to 140Ci 
hywcck 30. iind IO 150Ci i t t  tctn~."Althouph thc RRCmass 
pcaks iit tcrm to iihout 120Ci to I2Y; of nonprcgnant 
cxmtml valucs.' littlc is kncnvn a h u t  its cmlution thmugh- 
out prcgnancy. Mcat studics havc dcrivcd calculations of 
thc RRC' miis. from mcasurcmcnts of plasma volumc using 
Eviins blue dyc.':' '' Such indirect mcasurcmcnts iiK: not 
rccommcndcd-" hccausc w h o l c - M y  I+ct may vary widely. 
piirticuliirly in situations such as splcnomcgaly and prcp- 
niiny" ?h whcrc mnsidcrahlc rcdistrihution of blood vol- 
ume and hlcwxl flow takcs placc. In thc one study using 
appropriate methodology for thc scriitl mcasurcmcnt of 
totid RRC miis.,' thcrc was a dccrcasc in thc first trimcstcr 
of prcgniincy. followcd hy a gradual rcturn to nonprcgnant 
viilucs only hy wcck 30. and ii furthcr incrcasc in late 
prcgnibncy. 
I t  hiis hccn shown that thc RRC lifcspan rcmains 
unchiingcd during prcgnancy.' Modifications in thc total 
RRC miics should thcn hc a m u n t c d  for by variations in thc 
ratc of crythropoicsis. No quantitiitivc mcasurcmcnt of 
erythropoiesis is iiviiilahlc from thc litcraturc. cxccpt ncar 
tcrm.' hccausc of  the prohihitivc nccd to usc radioiron. 
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Methodology has been recently introduced for the measure- 
ment of serum TfR levels as a valuable alternative to 
ferrokinetics for the quantitative assessment of erythropoie- 
~is.7.~ Using this assay in the present study, we found that 
erythropoiesis was decreased in early pregnancy, normal- 
ized in the first part of the third trimester, and was 
moderately stimulated in late pregnancy, at delivery, and in 
the early postpartum. These data are consistent with the 
changes of RBC mass observed throughout pregnancy: 
Others" have measured TfR levels without other parame- 
ters of erythropoiesis in a small group of women, and 
observed increased levels in late pregnancy, but no change 
in the first part of pregnancy. The nature and standardiza- 
tion of the material measured in that assay is not well 
established% and direct comparison is difficult. 
There are theoretical interferences potentially preclud- 
ing the use of serum TfR levels as a measurement of 
erythropoiesis during pregnancy. First, the placenta is very 
rich in receptors quite similar to the erythroid TfR, allowing 
its use as immunogen and standard in the present a~say.8.~.'~ 
If placental TfR contributed significantly to circulating TfR 
levels, they would have caused an apparent overestimation 
of erythropoiesis in pregnancy, but this was obviously not 
the case. Second, functional iron deficiency beyond deple- 
tion of iron stores has been shown to produce an increase in 
serum TfR  level^.^*^^*^ The effect of iron stores on TfR levels 
was also observed in pregnancy. Women with deficient iron 
status had higher levels than women with marginal status 
and even more so than those with normal iron stores. When 
only women with normal stores were considered, mean TfR 
levels in each trimester were even more decreased, while 
iron deficient women had normal levels. Therefore, iron 
deficiency does not appear to interfere significantly with the 
conclusion that the rate of erythropoiesis is low in preg- 
nancy. 
Plasma expansion could cause an apparent reduction in 
the serum concentration of TfR by diluting the total 
number of soluble receptors in a larger volume. Correcting 
for plasma volume would give mean receptor levels of about 
5,290, 5,710, and 7,930 pg/L for women with normal iron 
stores, respectively, in the first, second, and third trimester. 
These levels are still well below expected values, particu- 
larly in view of levels of 23,258 f 5,640 and 32,900 4 8,352 
pg/L in patients with immune hemolytic anemia or hemoglo- 
bin H disease, where a similar degree of anemia (Hct 
35% f 5%) induced considerably higher rates of erythro- 
poiesis.' 
We attempted to identify factors responsible for de- 
creased erythropoiesis in pregnancy. In multivariate step- 
wise regression analysis, serum Epo contributed the most to 
the prediction of serum TfR. The correlation between 
serum TfR and Epo was strong in each period of pregnancy. 
Epo levels are best expressed in relation to the Hct?' We 
found an excellent correlation between Epo levels and Hct 
in 74 women with various degrees of anemia. Therefore, 
Epo levels measured in pregnant subjects could be related 
to predicted values calculated from the Hct. Absolute Epo 
levels increased throughout pregnancy and were in agree- 
ment with the Hct in the third trimester, at delivery, and in 
the early postpartum, but in the first two trimesters they 
were below predicted levels in the vast majority and low 
relatively to the Hct in 25% of the cases. The inverse linear 
relationship between log(Epo) and Hct, absent in the first 
trimester, progressively returned to normal as pregnancy 
advanced (Fig 2). 
Several physiologic adaptations to pregnancy may aug- 
ment oxygen supply to the kidney sensor, thus depressing 
Epo release in the first trimester. Erythrocyte 2,3-diphospho- 
glycerate increases early in pregnancy, producing a shift in 
the oxygen dissociation curve to the right.31 In the first 
trimester, the renal blood flow is considerably increased: 
but in the second half of pregnancy, a larger part of the 
expanded cardiac output is directed to the utero-placental 
and cutaneous circulations.26 These alterations in oxygen 
supply to the kidney could in part explain variations in Epo 
production rate throughout pregnancy and the early post- 
partum. Modifications in the endocrine status, such as the 
production of human placental lactogen, have also been 
suggested to possibly influence changes in Epo production 
and release during pregnan~y.'"~ 
We conclude that serum Epo levels, though increased 
over nonpregnant values, remain relatively low for the 
degree of anemia in the first part of pregnancy but return 
progressively to predicted levels thereafter. These changes 
in Epo production could explain the slowdown in erythropoi- 
etic activity observed in the first two trimesters and its 
normalization later in pregnancy. It should be emphasized 
that these alterations in the rate of erythropoiesis are 
adaptive changes that would certainly not require therapeu- 
tic intervention, such as the administration of rHuEpo. 
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